The defendants promised to fight the allegations:

Allison Schneider, a spokesperson for Novo Nordisk, described the claims in the lawsuit as "without merit" and said the company planned to vigorously defend itself against them. Novo Nordisk is trying to make insulin more affordable for patients, she said, citing an option called MyInsulinRx that costs $35.
Antoinette Forbes of Eli Lilly said the average monthly out-of-pocket cost for Lilly insulin is $20.48, that the company cut insulin prices by 70% and that it automatically caps monthly out-of-pocket costs at $35 or less wherever possible.
Mike DeAngelis of CVS said pharmaceutical companies alone are responsible for the prices they set in the marketplace for the products they manufacture. "Nothing in our agreements prevents drug manufacturers from lowering the prices of their insulin products, and we would welcome such an action," he said. "Allegations that we play any role in determining the prices charged by manufacturers for their products are false, and we intend to vigorously defend against this baseless suit."

Related: Eli Lilly agrees to $13.5M settlement in insulin lawsuit, agrees to $35 price cap

Last month, Eli Lilly settled a lawsuit brought by the state of Minnesota. It agreed to provide its insulin products at $35 per month to Minnesota residents with or without insurance for the next five years. Last May, it reached a settlement with insulin buyers following six years of litigation. The company agreed to pay a $13.5 million settlement and continue its cap on out-of-pocket costs for four years.

Instant Insights /

Baltimore sues Eli Lilly, Novo Nordisk over insulin price 'gouging'

More From HR Executive

Related Stories

Recommended For You